{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-064005","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.350565+00:00","generated_at":"2026-06-08T02:20:26.859459+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alkermes completes spin-off of oncology business into Mural; raises 2023 guidance","bullets":["On Nov 15, 2023, distributed 1 Mural share for every 10 Alkermes shares; MURA begins trading Nov 16.","FY2023 GAAP net income guidance raised to $250M–$280M from $225M–$265M; diluted EPS $1.46–$1.63.","Non-GAAP net income guidance raised to $270M–$300M from $230M–$270M; diluted EPS $1.57–$1.75.","Alkermes capitalized Mural with $275M cash; now a pure-play neuroscience company.","Operating expenses expected to drop ~$20M in last six weeks of 2023 due to separation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-064005","json":"https://secwatch.observer/filing/0000950170-23-064005.json","markdown":"https://secwatch.observer/filing/0000950170-23-064005.md","text":"https://secwatch.observer/filing/0000950170-23-064005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023064005/0000950170-23-064005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023064005/alks-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:20:26.859459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e95184d41a8ecef9356e75ea0427baf54d51407","claim":"Alkermes plc. completed a disposition involving Mural Oncology plc (closed 2023-11-15).","evidence_excerpt":"on November 15, 2023, the Company completed the Separation and the Distribution.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023064005/0000950170-23-064005-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Mural Oncology plc"},{"label":"Closing","value":"2023-11-15"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}